Development of a fluorescent loop-mediated isothermal amplification assay for rapid and simple diagnosis of bovine leukemia virus infection

Konomu NAGAO1), Ryohei MAKINO1), Francis Victor APEGO1), Hirohisa MEKATA2,3) and Wataru YAMAZAKI1,2)*

1)Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, 1-1 Gakuen Kibanadai-nishi, Miyazaki, Miyazaki 889-2192, Japan
2)Center for Animal Disease Control, University of Miyazaki, 1-1 Gakuen Kibanadai-nishi, Miyazaki, Miyazaki 889-2192, Japan
3)Organization for Promotion of Tenure Track, University of Miyazaki, 1-1 Gakuen Kibanadai-nishi, Miyazaki, Miyazaki 889-2192, Japan

ABSTRACT. Bovine leukemia virus (BLV) causes enzootic bovine leukosis (EBL), a condition that threatens the sustainability of the livestock industry. A fluorescent loop-mediated isothermal amplification (fLAMP) assay targeting BLV env sequences was developed and used to evaluate 100 bovine blood samples. Compared with a conventional real-time PCR (rPCR) assay, the fLAMP assay achieved 87.3% (62/71) sensitivity and 100% (29/29) specificity. The rPCR assay took 65 min, while the fLAMP assay took 8 min to 30 min from the beginning of DNA amplification to final judgement with a comparable limit of detection. The fLAMP is a potential tool for the rapid and simple diagnosis of BLV infection to supplement ELISA testing and can be used by local laboratories and slaughterhouses without special equipment.

KEY WORDS: BLV, bovine leukemia virus, enzootic bovine leucosis, fLAMP, fluorescent loop-mediated isothermal amplification
Fluorescent (fLAMP) reagents are commercially available, and this real-time amplification approach allows extremely rapid and accurate diagnosis through the use of an improved chain replacement enzyme and annealing analysis compared with tLAMP [4, 6, 17].

Here we used 100 bovine blood samples obtained from farms in the Kagoshima, Miyazaki and Oita prefectures in Japan to develop an fLAMP assay that we compared with a published real-time PCR assay.

From March to June 2017, blood samples of 20 Brown-Swiss, 85 Holstein and 304 Japanese Black cattle were collected from five farms in Kagoshima, Miyazaki and Oita prefectures, Japan. An evacuated tube containing EDTA was used for blood collection, all samples were centrifuged at 1,500 × g for 5 min, and the plasma was used for the anti-BLV antibody-ELISA (BLV ELISA test; JNC Co., Ltd., Tokyo, Japan) according to manufacturer’s instructions, including with previously described modifications [8, 9].

Genomic DNA extraction was performed according to our previous study [9]. Briefly, among 409 blood samples, 80 seropositive and 20 seronegative samples were randomly chosen. The buffy coat was collected from the centrifuged EDTA-treated blood sample described above, and genomic DNA was extracted using a Wizard Genomic DNA Purification Kit (Promega, Fitchburg, WI, U.S.A.) in accordance with the manufacturer’s instructions. Using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, U.S.A.), the DNA concentration was measured and adjusted to 20 ng/µl using distilled water. The genomic DNA of fetalm lamb kidney cells infected with BLV (FLK-BLV) [21] was extracted in the same manner described above for the comparative determination of the LOD. Genomic DNAs were used immediately, otherwise they were stored at −20 or −80°C.

We used Primer Explorer V5 software (Fujitsu System Solutions Ltd., Tokyo, Japan) to design a new primer set based on BLV env nucleotide sequences in an alignment of 401 BLV partial env gene msas/clustalo/), as well as Jalview to identify conserved sequences. We used Clustal omega for multiple alignment of 180 BLV complete env sequences (https://www.ebi.ac.uk/Tools/msa/clustalo/), as well as Jalview to identify conserved env nucleotide sequences in an alignment of 401 BLV partial env gene sequences [22]. Details of the primers are shown in Table 1. The predicted specificities of the six primers were determined using the Basic Local Alignment Search Tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The fLAMP assay was performed using a Genie III (OptiGene, Horsham, U.K.). Amplification was performed at 67°C for 30 min, followed by inactivation of enzymatic activity at 98°C for 2 min, and cooling to 80°C for annealing analysis with ramping at 0.05°C/sec. The 25-µl fLAMP reaction comprised 15 µl of an isothermal master mix (ISO-002, Optigene), 0.4 µl each of FIP and BIP primers (100 pmol/µl), 0.2 µl each of LF and LB primers (100 pmol/µl), 0.05 µl each of F3 and B3 primers (100 pmol/µl), 3.7 µl of nuclelease-free water, and 5 µl of the DNA template. All LAMP primers were produced using column-grade purification methods by Hokkaido System Science (Sapporo, Japan). When the fluorescence intensity reached 20,000 within a 30-min amplification, and the annealing temperature (Ta) value ranged between 89.0 and 92.0°C, the results were interpreted as positive. Time of positivity (Tp) was automatically calculated. Details of the primers and probes are shown in Table 1.

| Assay primer | Sequences (5′–3′) | Sequence of the FLK strain (Genbank accession no. LC164083) | Reference |
|--------------|-------------------|------------------------------------------------------------|-----------|
| Fluorescent LAMP | BLV-2_FIP | GGCCARTAGATCTTAGGATAGCCA-TTTTCCTTTCTGTGCCAAGGTATCC | 5,100–5,077-(TTTT)-5,032–5,052 | This study |
| | BLV-2_BIP | GAGCCAGGCCATGCC-TTTTCCTTTCTTTCCCATATAGGCCTCC | 5,127–5,143-(TTTT)-5,179–5,162 |
| | BLV-2_F3 | CCATTGACCAAATATAGGAGGC | 4,998–5,019 |
| | BLV-2_B3 | CATCAGACGACGATGCC | 5,180–5,196 |
| | BLV-2_LF | TTACAGATTCAAGGTTAT | 5,075–5,055 |
| | BLV-2_LB | CACATATGATTAGCGACCC | 5,143–5,160 |
| Real-time PCR | MRBLVL | CCTAATTCTCTTAACTA | 2,326–2,345 |
| | MRBLVR | GTACCCCGAAAGATGGAATTA | 2,445–2,426 |
| | MRBLV probe | 6FAM-GAACGCCTCCAGGCCCTTCA-BHQ1 | 2,346–2,365 |

Sequence of the FLK strain (Genbank accession no. LC164083) was determined by the Genie III (OptiGene, Horsham, U.K.). Amplification was performed at 67°C for 30 min, followed by inactivation of enzymatic activity at 98°C for 2 min, and cooling to 80°C for annealing analysis with ramping at 0.05°C/sec. The 25-µl fLAMP reaction comprised 15 µl of an isothermal master mix (ISO-002, Optigene), 0.4 µl each of FIP and BIP primers (100 pmol/µl), 0.2 µl each of LF and LB primers (100 pmol/µl), 0.05 µl each of F3 and B3 primers (100 pmol/µl), 3.7 µl of nuclelease-free water, and 5 µl of the DNA template. All LAMP primers were produced using column-grade purification methods by Hokkaido System Science (Sapporo, Japan). When the fluorescence intensity reached 20,000 within a 30-min amplification, and the annealing temperature (Ta) value ranged between 89.0 and 92.0°C, the results were interpreted as positive. Time of positivity (Tp) was automatically calculated. Details of the primers and probes are shown in Table 1.

| Sequence of the FLK strain (Genbank accession no. LC164083) was determined by the Genie III (OptiGene, Horsham, U.K.). Amplification was performed at 67°C for 30 min, followed by inactivation of enzymatic activity at 98°C for 2 min, and cooling to 80°C for annealing analysis with ramping at 0.05°C/sec. The 25-µl fLAMP reaction comprised 15 µl of an isothermal master mix (ISO-002, Optigene), 0.4 µl each of FIP and BIP primers (100 pmol/µl), 0.2 µl each of LF and LB primers (100 pmol/µl), 0.05 µl each of F3 and B3 primers (100 pmol/µl), 3.7 µl of nuclease-free water, and 5 µl of the DNA template. All LAMP primers were produced using column-grade purification methods by Hokkaido System Science (Sapporo, Japan). When the fluorescence intensity reached 20,000 within a 30-min amplification, and the annealing temperature (Ta) value ranged between 89.0 and 92.0°C, the results were interpreted as positive. Time of positivity (Tp) was automatically calculated. Details of the primers and probes are shown in Table 1.

| Reference | |
|-----------|---|
| Rola-Luszczak et al., 2013 [16]; OIE, 2018 [23] | |

[5, 14]. Fluorescent (fLAMP) reagents are commercially available, and this real-time amplification approach allows extremely rapid and accurate diagnosis through the use of an improved chain replacement enzyme and annealing analysis compared with tLAMP [4, 6, 17].

This study...
FLAMP assay identifies BLV infection

and cloned into the pEX-K4J1 vector by Eurofins Genomics, Co., Ltd (Tokyo, Japan). The amplified sequence was used to calculate the proviral loads in clinical samples as well as to prepare serial 10-fold serial dilutions of the DNA templates for LOD determination. Further, the FLAMP assay targeting the LTR region was performed to compare the LOD according to a published method [5]. Two DNA templates were used for further comparisons of different genotypes of the FLK strain (genotype 1) and a BLV-genomic DNA obtained from a naturally BLV-infected cow in Miyazaki (JA366, genotype 3). Ten-fold serial dilutions in distilled water were prepared, and the fLAMP, tLAMP and rPCR assays were performed as described above. When a sample was positive or negative in duplicate analyses, the result was interpreted as a positive in all three assays.

We retrieved 401 BLV complete and partial env sequences from GenBank to design a BLV-specific LAMP primer set. The locations and nucleotide variations of the LAMP primers representing 180 complete env sequences are shown in Fig. 1. Although LAMP primers were derived from the conserved region of env, to maintain amplification speed and accuracy, mixed bases were incorporated into the FIP and B3 primers because of the variability of the target sequences that introduce mismatches at the crucial regions between target sequences and primers (Table 1 and Fig. 1).

In a preliminary test, we attempted to design a LAMP primer set using well-conserved pol sequences. The pol gene was not amplified by any LAMP primer set that we designed using Primer Explorer V5 software. This may be explained by the low GC content of pol. Therefore, we chose the conserved sequence in env to design the specific LAMP primer set. To determine primer specificities, each of the six primers representing eight distinct regions of env were analysed using BLAST to query GenBank. There were no matches between the first six bases of the eight primer-binding regions with non-BLV sequences (Table 1). Further, 20 samples did not yield CT values using the BLV-specific real-time PCR (rPCR) assay, and their values were significantly below the threshold of baseline absorbance in the anti-BLV antibody-ELISA. These samples were all BLV-negative in the fLAMP assay.

Further, false-positive signals were not detected (Fig. 2, Table 2).

We used 100 bovine clinical blood samples, comprising 80 ELISA-positive and 20 ELISA-negative samples, to evaluate the performance of the BLV specific fLAMP assay. The results were compared with those of the rPCR assay [16, 23]. As shown in Table 2 and Fig. 2, among the 80 ELISA-positive samples, 62 and 71 were positive and 18 and 9 were negative in the fLAMP and rPCR assays, respectively. The 20 ELISA-negative samples were negative in both assays. Compared with the ELISA results, the fLAMP assay achieved 77.5% (62/80) sensitivity and 100% (20/20) specificity and the rPCR assay showed 87.3% (62/71) sensitivity and 100% (29/29) specificity. The rPCR assay required 65 min from the beginning of reaction to the final extension step. In contrast, the fLAMP assay yielded 62 positive results between 7 min, 15 sec and 28 min (mean Tp 10 min 8 sec ± SD 3 min 23 sec). Among the 13-samples that were low proviral loads (2–39 copies per 100 ng DNA), corresponding to weak rPCR positives (CT range, 35.37–39.00), the fLAMP assay generated four true-positives and nine false-negatives (Table 2, Fig. 2, and Table S1). The fLAMP assay did not detect BLV sequences in 29 samples comprising nine rPCR-negative/ELISA-positive and 20 rPCR- and ELISA-negative samples (Table 2).

A comparison between fLAMP and rPCR data sets is shown in Fig. 2. The rPCR assay yielded 71 positives with 2–25,883 proviral loads (copies per 100 ng DNA), corresponding to CT values ranging from 24.94 to 39.00 (mean CT, 29.74 ± SD 3.86). In contrast to the ELISA results, the remaining nine samples were negative in the rPCR assay. A 10−3-dilution of the BLV reference strain FLK (genotype 1) returned a “weak” CT value (39.32) in one of two duplicate samples (Table 3). The LODs of the fLAMP assay were comparable, or 1-log less sensitive, compared with those of the rPCR and tLAMP assays (Table 3). The difference in the LOD values may explain why nine samples were fLAMP-negative but rPCR-positive.
The fLAMP assay was remarkably rapid. Two reports describe the development of a LAMP assay for BLV based on the LTR region [5] and its application to routine surveys [14]. However, these studies used a tLAMP assay, requiring amplification times (22–60 min) [5, 14] that are significantly longer compared with those reported here (8–30 min). In our present study, the tLAMP and fLAMP assays took 16–34 min and 8–25 min to amplify target DNAs, respectively (Table 3). Further, the tLAMP assay is unable to confirm the specificity of the amplified product as judged by annealing temperatures [4, 6, 17]. For this purpose, the tLAMP assay requires an open reaction tube for electrophoresis, which may be susceptible to contamination.

A diagnostic system based on single genomic targets risks a false-negative diagnosis [20]. For this reason, the development of a fluorescent-based assay using a distinct target gene with high specificity should be useful as a safeguard. Therefore, the fLAMP provides a potential tool for the rapid and simple diagnosis of BLV infection to supplement ELISA testing and can be used by local laboratories and slaughterhouses without special equipment.

The worldwide spread of BLV emphasizes the requirement for early diagnosis and control of disease to minimize economic...
losses, as well as to ensure animal welfare. The fLAMP assay was applied to rapid and simple diagnosis of human and veterinary infectious diseases [4, 6, 17]. Specific amplification using the LAMP assay occurs at a constant temperature, minimizing reliance on expensive equipment [2, 24]. Consequently, these assays may facilitate the development of an inexpensive test. For example, the fLAMP takes 8–30 min from the beginning of amplification and <10 min for enzyme inactivation and annealing to final judgment.

The application of the LAMP assay for rapid screening of clinical samples would save time and costs, enabling detection of BLV-positive cases during the early phase of infection because of its lower or equivalent LODs compared with those of conventional PCR and nested PCR assays [5, 14]. Further, the fLAMP assay can be used at farms, slaughterhouses, and wholesale markets in combination with direct DNA detection techniques of clinical samples [4, 17], which would enhance the utility of fLAMP when performed using a portable real-time detector such as the Genie III [4, 6].

As ideal quantitative tools, digital LAMP assays have been developed for clinically important infectious diseases [7, 18]. In the future, application of the BLV-specific LAMP primers described here to the LAMP assay should facilitate more precise and rapid quantification of BLV as a countermeasure in countries with endemic BLV infections. The determination of the precise BLV proviral loads of individual cattle within a herd and the isolation of cattle with high BLV proviral loads is essential to develop an effective strategy to control the transmission of BLV [8–11]. In conclusion, the fLAMP assay serves as a simple and rapid tool that has the potential for effectively controlling of BLV infection.

CONFLICT OF INTEREST. We declare that there are no conflicts regarding the subject matter of the manuscript.

ACKNOWLEDGMENTS. This research was supported by grants from JSPS KAKENHI Grant Number JP18K05535, and Training Program for Asian Veterinarians from the Japan Race Horse Health Association. We thank Junko Sasaki and Mari Yamamoto for technical assistance.

REFERENCES

1. Fechner, H., Blankenstein, P., Looman, A. C., Elwert, J., Geue, L., Albrecht, C., Kurg, A., Beier, D., Marquardt, O. and Ebner, D. 1997. Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally infected cattle. *Virology* 237: 261–269. [Medline] [CrossRef]

2. Hayashida, K., Kajino, K., Hachaamba, L., Namangala, B. and Sugimoto, C. 2015. Direct blood dry LAMP: a rapid, stable, and easy diagnostic tool for Human African Trypanosomiasis. *PLoS Negl. Trop. Dis.* 9: e0003578. [Medline] [CrossRef]

3. Heenemann, K., Lapp, S., Teifke, J. P., Fichtner, D., Mettenleiter, T. C. and Vahlenkamp, T. W. 2012. Development of a bovine leukemia virus polymerase gene-based real-time polymerase chain reaction and comparison with an envelope gene-based assay. *J. Vet. Diagn. Invest.* 24: 649–655. [Medline] [CrossRef]

4. Howson, E. L. A., Armson, B., Madi, M., Kasanga, C. J., Kandusi, S., Sallu, R., Chepkwony, E., Siddle, A., Martin, P., Wood, J., Mioulet, V., King, D. P., Lembo, T., Cleaveland, S. and Fowler, V. L. 2017. Evaluation of two lyophilized molecular assays to rapidly detect foot-and-mouth disease virus directly from clinical samples in field settings. *Transbound. Emerg. Dis.* 64: 861–871. [Medline] [CrossRef]

5. Komiyama, C., Suzuki, K., Miura, Y. and Sentsui, H. 2009. Development of loop-mediated isothermal amplification method for diagnosis of bovine leukemia virus infection. *J. Virol. Methods* 157: 175–179. [Medline] [CrossRef]

6. Kurosaki, Y., Magassoubba, N., Oleniniiy, O. K., Cherif, M. S., Sakabe, S., Takada, A., Hirayama, K. and Yasuda, J. 2016. Development and evaluation of reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay coupled with a portable device for rapid diagnosis of Ebola virus disease in Guinea. *PLoS Negl. Trop. Dis.* 10: e0004472. [Medline] [CrossRef]

7. Ma, Y. D., Chang, W. H., Luo, K., Wang, C. H., Liu, S. Y., Yen, W. H. and Lee, G. B. 2018. Digital quantification of DNA via isothermal amplification on a self-driven microfluidic chip featuring hydrophilic film-coated polydimethylsiloxane. *Biosens. Bioelectron.* 99: 547–554. [Medline] [CrossRef]

8. Mekata, H., Sekiguchi, S., Konnai, S., Kirino, Y., Honkawa, K., Nonaka, N., Horii, Y. and Norimine, J. 2015a. Evaluation of the natural perinatal transmission of bovine leukaemia virus. *Vet. Rec.* 176: 254. [Medline] [CrossRef]

9. Mekata, H., Sekiguchi, S., Konnai, S., Kirino, Y., Horii, Y. and Norimine, J. 2015b. Horizontal transmission and phylogenetic analysis of bovine leukaemia virus in two districts of Miyazaki, Japan. *J. Vet. Med. Sci.* 77: 1115–1120. [Medline] [CrossRef]

10. Mekata, H. 2016. Diagnosing bovine leukaemia virus infection. *Jpn. J. Large Anim. Clin.* 6: 221–226 (in Japanese with English summary). [CrossRef]

11. Murakami, K., Kobayashi, S., Konishi, M., Kameyama, K., Yamamoto, T. and Tsutsui, T. 2011. The recent prevalence of bovine leukemia virus (BLV) infection among Japanese cattle. *Vet. Microbiol.* 148: 84–88. [Medline] [CrossRef]

12. Notomi, T., Okayama, H., Masubuchi, H., Yoneyama, T., Watanabe, K., Amino, N. and Hase, T. 2000. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* 28: E63. [Medline] [CrossRef]

13. Nuotio, L., Rusanen, H., Sihvonen, L. and Neuvonen, E. 2003. Eradication of enzootic bovine leukosis from Finland. *Prev. Vet. Med.* 59: 43–49. [Medline] [CrossRef]

14. Okuwa, Y., Miyamoto-Hayashi, M., Tanaka, T., Hayakawa, Y. and Inoshima, Y. 2017. Simple and rapid method for routine screening of bovine leukemia virus by loop-mediated isothermal amplification assay. *J. Vet. Med. Sci.* 79: 137–140. [Medline] [CrossRef]

15. Parida, M. 2008. Rapid and real-time detection technologies for emerging viruses of biomedical importance. *J. Biosci.* 33: 617–628. [Medline] [CrossRef]

16. Rola-Luszczak, M., Finnegan, C., Olech, M., Choudhury, B. and Kuzmák, J. 2013. Development of an improved real time PCR for the detection of bovine leukaemia provirus nucleic acid and its use in the clarification of inconclusive serological test results. *J. Virol. Methods* 189: 258–264. [Medline] [CrossRef]

17. Sabike, I. I. and Yamazaki, W. 2019. Improving detection accuracy and time for *Campylobacter jejuni* and *Campylobacter coli* in naturally infected live and slaughtered chicken broilers using real-time fluorescent LAMP approach. *J. Food Prot.* 82: 189–193. [Medline] [CrossRef]

18. Schoepf, N. G., Schlappi, T. S., Curtis, M. S., Butkovich, S. S., Miller, S., Humphries, R. M. and Ismagilov, R. F. 2017. Rapid pathogen-specific
phenotypic antibiotic susceptibility testing using digital LAMP quantification in clinical samples. Sci. Transl. Med. 9: 9. [Medline] [CrossRef]

19. Schwartz, I. and Lévy, D. 1994. Pathobiology of bovine leukemia virus. Vet. Res. 25: 521–536. [Medline]

20. Shirato, K., Semba, S., El-Kafrawy, S. A., Hassan, A. M., Tolah, A. M., Takayama, I., Kageyama, T., Notomi, T., Kamitani, W., Matsuyama, S. and Azhar, E. I. 2018. Development of fluorescent reverse transcription loop-mediated isothermal amplification (RT-LAMP) using quenching probes for the detection of the Middle East respiratory syndrome coronavirus. J. Virol. Methods 258: 41–48. [Medline] [CrossRef]

21. Van Der Maaten, M. J. and Miller, J. M. 1976. Replication of bovine leukemia virus in mono-layer cell cultures. Bibl. Haematol. 43: 360–362.

22. Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. and Barton, G. J. 2009. Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189–1191. [Medline] [CrossRef]

23. World Organization for Animal Health (OIE). 2018. Enzootic bovine leucosis (Chapter 2.4.10). pp. 1–12. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Paris.

24. Yamazaki, W., Mioulet, V., Murray, L., Madi, M., Haga, T., Misawa, N., Horii, Y. and King, D. P. 2013. Development and evaluation of multiplex RT-LAMP assays for rapid and sensitive detection of foot-and-mouth disease virus. J. Virol. Methods 192: 18–24. [Medline] [CrossRef]